ArticleJournal of epidemiology and global health2026
Impact of Therapeutic Inertia on Glycemic Control and Diabetes-Related Complications in Type 2 Diabetes: A 3-Year Retrospective Cohort Study.
Article in Journal of epidemiology and global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTherapeutic inertia is a major barrier to optimal glycemic control in type 2 diabetes (T2DM), yet its impact in low-resource settings is not well-documented. This retrospective cohort study investigated the effect of therapeutic inertia on treatment outcomes in patients with T2DM receiving care at a tertiary hospital in southern Ethiopia.
methodsA retrospective cohort study was conducted among 159 adult ambulatory T2DM patients between June 2020 and 2023. Data were collected from medical records. The primary outcome was poor treatment outcome, defined as fasting blood glucose > 130 mg/dL or development of a new diabetes-related complication. Exposure was defined as failure to intensify treatment within three months of uncontrolled glycemia. Cox proportional hazard models were used to assess the association between therapeutic inertia and poor treatment outcomes.
resultsThe medical records of 159 T2DM patients were reviewed. Poor treatment outcomes were common in the therapeutic inertia group (68.6%). The therapeutic inertia exposure group was significantly associated with an increased risk of poor treatment outcomes, with an adjusted HR of 1.927 (95% CI: 1.201-3.092, p = 0.007). As a secondary analysis, factors such as physician qualification (p = 0.001), presence of comorbidities (p = 0.024), and the presence of neuropathy (p = 0.02) and nephropathy (p = 0.011) were significantly associated with therapeutic inertia.
conclusionTherapeutic inertia was significantly associated with worse treatment outcomes in this cohort. Healthcare systems should implement strategies to promote proactive diabetes management, while recognizing that therapeutic inertia is a complex issue influenced by patient, provider, and system factors. Future research should focus on identifying and overcoming the contextual barriers to timely treatment intensification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.